How the Lack of R&D at Big Pharma Is Boosting Small Biotechs

The Life Sciences Report | |

The recent pullback in biotech shares has not changed the time-tested theory of investing in small-cap drug development companies. Good or bad data will continue to move shares. In this interview

Stocks Under $10: Sell Rated Biomed/Genetics Companies in the Medical Space

Richard Suttmeier | |

At we show that the Medical sector 10.1% overvalued with the Medical Biomed/Genetics 11.9% overvalued. All 14 stocks in today’s table have complete ValuEngine data and have

Oncothyreon Shares Pummeled as Cancer Vaccine Misses Endpoint

Andrew Klips | |

Shares of Oncothyreon Inc. (ONTY) fell hard Wednesday morning upon reports that pivotal Phase III trials for its L-BLP25 (formerly “Stimuvax”) missed on the primary endpoint of improving the

Equities Sector Coverage: Is the Bull Market Over?

Sector Recap | |

The Dow Jones Industrial Average declined to 12,734.86 on Tuesday afternoon after momentum on the daily chart shifted to negative at Monday’s close. The NASDAQ declined to 2900.28 on Tuesday

Equities Sector Coverage: Wall Street Pushes Higher

Sector Recap | |

The ISM Manufacturing Index rose to 54.1 in January from 53.1 in December. Construction Spending rose by 1.5% in December. The Dow Jones Industrial Average traded higher at the open to 12,784.62

Fed Statement Wakes Up Wall Street

Sector Recap | |

The Federal Open Market Committee announced that the federal funds rate will remain at zero to 0.25% at least through late 2014 on significant downside risks from global financial stress. The Dow

Sponsored Financial Content

Market Movers